Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Dare Bioscience, Inc. (DARE)
|
Add to portfolio |
|
|
|
| Price: |
$1.94
| | Metrics |
| OS: |
87.8
|
M
| |
|
|
| Market cap: |
$170
|
M
| |
|
|
|
Net cash:
|
$13.3
|
M
| |
$0.15
|
per share
|
|
EV:
|
$157
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Revenue growth | 20.0% | | | | | | -100.0% | 1233.3% |
| Cost of goods sold | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Gross margin | 0.0% | 0.0% | | | | | | 100.0% |
| Research and development | 30.6 | 20.8 | 8.5 | 6.4 | 1.0 | 0.1 | 25.9 | 11.8 |
| General and administrative | 8.4 | 6.5 | 5.3 | 4.7 | 2.7 | 0.2 | 11.2 | 8.6 |
| EBIT | -39.1 | -27.4 | -14.3 | -11.7 | -3.7 | -0.6 | -37.2 | -24.3 |
| EBIT margin | -39068.5% | -32882.8% | | | | | | -30321.3% |
| Pre-tax income | -38.7 | -27.4 | -14.3 | -16.8 | -11.5 | -0.7 | -39.6 | -23.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -38.7 | -27.4 | -15.1 | -16.7 | -11.5 | -0.7 | -39.6 | -23.3 |
| Net margin | -38696.1% | -32889.3% | | | | | | -29177.5% |
| |
| Diluted EPS | ($0.63) | ($0.91) | ($0.97) | ($1.56) | ($3.56) | ($0.81) | ($1.56) | ($1.60) |
| Shares outstanding (diluted) | 61.2 | 30.1 | 15.6 | 10.7 | 3.2 | 0.8 | 25.4 | 14.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|